Dozens of patent challenges filed earlier this decade against core intellectual property held in the EU by array companies will likely conclude within the next few years, according to some attorneys familiar with the cases.

Additionally, the EPO remains the favored route to invalidate a company's IP in Europe because it is less expensive than opposing IP in individual countries and has farther reaching results, the attorneys say.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.